Navigation Links
Haemonetics Sets Date for Investor/Analyst Meeting
Date:4/24/2013

BRAINTREE, Mass., April 24, 2013 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that it will host its annual investor and analyst meeting on Thursday, May 16th from 10:00 am to 3:00 pm at The Seaport Hotel in Boston, Massachusetts.

(Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO)

The agenda for the meeting includes updates on the following:

  • Hospital Based Blood Management Solutions / Emerging Markets
  • R&D Update Including Automated Whole Blood, OrthoPAT® Advance™ and Future New Products
  • Commercial Value Creation & Capture (" VCC")
  • Operations Overview and Strategy
  • Guidance and Aspirational Goals

The meeting is open to analysts, shareholders, and others in the investment community by invitation. Invitations will follow shortly and attendees must register by May 3rd. On-line registration will be utilized and instructions for registration will accompany invitations.

Other audiences are welcome to participate in the meeting via live webcast. Webcast details are posted on the following link:  http://www.media-server.com/m/p/64xj58en.  For more information, please contact Bryanne Salmon at (781) 356-9613 or bsalmon@haemonetics.com.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

CONTACT: Investor Relations
Gerry Gould (781) 356-9402
gerry.gould@haemonetics.com
Bryanne Salmon (781) 356-9613                                                                                                 bsalmon@haemonetics.com  


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
2. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
3. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
4. Haemonetics Provides Update on Hemerus Medical, LLC Acquisition
5. Haemonetics Reports 3rd Quarter Fiscal 2013 Revenue Up 29% and $0.50 Adjusted EPS; Year-To-Date Organic Revenue Up 3%; Reaffirms Fiscal 2013 Adjusted EPS Guidance of $1.65-$1.70
6. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
7. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
8. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
9. Stereotaxis Epoch™ Solutions Momentum Drives Strong Presence at the Heart Rhythm Society (HRS) Annual Meeting
10. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
11. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017   Royal Philips (NYSE: ... in health technology, today announced 510(k) clearance from ... market its ElastQ Imaging capability, further expanding the ... ElastQ Imaging enables simultaneous imaging of tissue and ... the diagnosis of various liver conditions. With ElastQ ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
(Date:2/27/2017)... , Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) ... Adam Craig , M.D., Ph.D., as President and Chief Executive ... March 20, 2017. Dr. Craig succeeds Richard Love , ... the company,s Board of Directors.  Dr. Craig has over 20 ... both the US and Europe . ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based ... In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... company had 800 customers and 2,250 RCEs at the time of acquisition. In ...
(Date:2/27/2017)... , ... February 27, 2017 , ... New Jersey ranks ... among all types and genders. And the need for advanced services is growing. ... its top-rated cancer care program, in collaboration with their non-profit partners in their fight ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... NuevaCare, a ... as diverse as Millbrae, Belmont, and Palo Alto, is proud to announce an important ... Bay Area consumers look for home care close to home, and by having city-specific ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ODH, Inc.™ ... Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director ... to use behavioral health analytics to improve Medicaid population health management. , ODH will ...
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
Breaking Medicine News(10 mins):